Industry

2025.10.01

Dear Valued Clients and Partners, Thank you for your continued trust and support. To accommodate our growing business needs, we are pleased to announce that our office will be relocating to a new address starting Monday, October 13, 2025. For all future business correspondence, inquiries, payment notifications, and communications, please update your records with the following information. We apologize for any inconvenience this may cause. We sincerely look forward to continuing our partnership with you and achieving greater success together. New Address: 7F, No. 226, Section 3, Zhonghua Road, Xinzhuang District, New Taipei City 242, Taiwan Phone (Unchanged): +886-2-2656-1168 ;...

2025.07.16 Jackson Lin

The U.S. FDA 510(k) clearance data from the second quarter of 2025 provides critical insights into the development of the global digital health industry. This analysis focuses on the market opportunities and competitive realities revealed by this quarter's data, aiming to offer a strategic reference for MedTech companies, startups, and investment institutions. Key Takeaways Market Focus: AI imaging software (QIH) has become the most popular FDA 510(k) regulatory pathway in Q2 2025, with 24 clearances. Competitive Barrier: The key barrier to entry is "regulatory experience." "Expert-level" players with 6+ historical clearances dominate nearly 45% of the market. Efficiency Gap: Expert-level...

2025.06.26 Jackson Lin

  As the dust settles from RAN#108 in Prague, the industry now has the approved 6G Study Item (RP-251881)—the first concrete blueprint for the next generation of wireless. While it's easy to focus on the individual technical objectives, a deeper look reveals a crucial strategic pivot that will define the success of our contributions for the next decade. The core insight from Wispro's analysis is this: The final 6G Study Item reveals a deliberate pivot from a collection of siloed features to a single, unified design philosophy that prioritizes long-term simplicity and harmonization. Here’s what that means for the 3GPP...

2025.06.17

Global Recognition from a Leading IP Authority The IAM Patent 1000 is a globally trusted and authoritative guide for companies seeking top-tier patent services. As one of the most prestigious annual rankings in the intellectual property industry, it is compiled by the team at Intellectual Asset Management through months of in-depth interviews and market analysis, covering over 50 jurisdictions worldwide. Being listed in this guide signifies exceptional recognition for a firm’s professional capabilities, service quality, and client trust on the global stage.   Dual Recognition Underscores Wispro’s IP Strategy Leadership WISPRO Technology Consulting Corporation makes its debut in the 2025...

2025.06.10 Jackson Lin

The industry stands at a pivotal moment as we head into 3GPP RAN#108. The agenda is set, the contributions are in, and the critical task of defining the initial path for 6G is upon us. The sheer volume of technical documents for the 6G Study Item (SI) presents a significant challenge for all involved. At Wispro, we believe advanced tools can help manage this complexity. We used an AI-assisted approach to process and synthesize 170+ TDocs for agenda items 16, 16.1, and 16.2. Our goal was not to predict an outcome, but to create a consolidated, data-driven view to help...

2025.05.21 Jackson Lin

Leveraging Innovative Data Analytics to Empower MedTech Companies with Foresight for Strategic Growth In the fiercely competitive and rapidly evolving global medical device industry, the ability to accurately grasp market dynamics, discern competitive landscapes, and formulate forward-thinking strategies has become paramount for sustainable corporate success. Against this backdrop, a critical determinant of success lies in transforming vast amounts of data into strategically significant business intelligence. Leveraging data- and intelligence-driven insights is essential to support and guide medical device companies, startups, and investment institutions in making informed, data-driven decisions. The Sleeping Giant: Re-evaluating the Strategic Value of Public FDA 510(k) Database...

2025.05.14 Jackson Lin

This article doesn't aim to provide definitive answers. Instead, through actual FDA clearance data, it presents the real-time dynamics at the forefront of the MedTech market: showing who has successfully established their presence, who is quickly catching up, and where you stand. Key Insight for Decision-Making: The Value of FDA MedTech Data Precise and timely decisions are the cornerstone of success in the rapidly evolving medical device industry. If you are evaluating your next product development direction, potential market expansion regions, tracking the latest moves of your key competitors, or screening potential investment targets, the latest FDA Class II 510(k)...

2025.04.23 Rico Cho

As part of our continuous efforts to deepen international partnerships in the field of intellectual property, Vice President Rico Cho recently visited Ms. Tanaka, Patent Attorney at ASAMURA IP P.C., during his business trip to Japan. The meeting aimed to maintain a strong working relationship, explore future collaboration opportunities, and introduce PatentCloud's AI-powered platform. Both parties engaged in productive discussions on how emerging technologies can enhance IP analysis and decision-making.